51Թ

The 2018 BIC Retreat

Monday, December 10, 2018 08:45to18:00

 Usine C, 1345 Avenue Lalonde, Montréal, QC, H2L 5A9, CA/bicCategory: BIC Lectures

MEG@51ԹComprehensive Training (Second Edition)

Monday, November 16, 2015toFriday, November 20, 2015

It is with great pleasure that we are announcing the 2nd edition of the MEG@51ԹComprehensive Training Program in 2015.3801 rue University, Montreal, QC, H3A 2B4, CA/bicCategory: MNI

Project to create AI model for ALS receives Génome Québec funding

Published: 17 March 2025

$400,000 will fuel public-private collaboration to discover new disease biomarkers...

Open Science project funded for $1.5M

Published: 12 November 2024

YCharOS antibody characterization platform addresses the “reproducibility crisis” in research...

Genetic sequencing project receives more than $8 million in funding

Published: 18 March 2025

NeuRo Genomics Initiative will help better understand rare and aging-related neurological disorders affecting Canadians...

Six principal investigators from The Neuro receive CIHR grants

Published: 10 February 2025

Projects include important research on Parkinson’s, glioblastoma and dementia  

Latest Alzheimer’s drug shown less effective in females than males

Published: 18 March 2025

Since becoming only the second Alzheimer’s-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD...

Expanding access to specialized healthcare across Quebec: ECHO Superhub at The Neuro

Published: 25 March 2025

Free, online training program strengthens training and brings specialized care to communities across Quebec...

Prescribing anti-swelling drug reduces immune response weeks after last dose

Published: 26 February 2025

Mapping immune cell diversity reveals dexamethasone’s impact on brain cancer immunotherapy...

Pages

                           

The Neuro logo51Թlogo

                                                                                                                 

Back to top